Cardiogenic Shock Clinical Trial
Official title:
Management of Acute Cardiogenic Shock at the New Brunswick Heart Centre
In Atlantic Canada, acute myocardial infarction occurs at a rate of 2.9 % of the population and is the most common cause of cardiogenic shock (CS). In many studies, acute myocardial infarction accounts for up to 80% of the patients with CS. While there are different methods of treating patients with CS, the rate of mortality has not significantly improved over the years and remains as high as 50%. Recent studies have shown that a multi-modal, team-based approach can help improve patient outcomes; however, such a standardized approach is yet to be implemented in the New Brunswick Heart Centre (NBHC). The study aims to understand the difference in outcomes between two groups of patients treated for CS: SHOCK TEAM versus non-SHOCK TEAM. This is a retrospective study of 168 patients using the data from NBHC registry and patient charts. The study duration is 1 year. The primary outcome is hospital survival. Secondary outcomes include time from diagnosis to invasive monitoring and intervention. All data will be analyzed statistically between the two groups. The end goal of the study is to establish standard guidelines to treat CS patients and improve patient survival.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03283995 -
Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
|
||
| Active, not recruiting |
NCT04325035 -
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
|
Phase 2 | |
| Active, not recruiting |
NCT05100836 -
SURPASS Impella 5.5 Study
|
||
| Not yet recruiting |
NCT05106491 -
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
|
N/A | |
| Completed |
NCT02301819 -
ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock
|
N/A | |
| Completed |
NCT01367743 -
Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock
|
Phase 4 | |
| Recruiting |
NCT05728359 -
Genomic Determinants of Outcome in Cardiogenic Shock
|
||
| Recruiting |
NCT05699005 -
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO
|
Phase 1 | |
| Not yet recruiting |
NCT06338345 -
Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients
|
N/A | |
| Completed |
NCT03436641 -
Microcirculation in Cardiogenic Shock
|
||
| Recruiting |
NCT03313687 -
SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
|
||
| Recruiting |
NCT05506449 -
The RECOVER IV Trial
|
N/A | |
| Completed |
NCT04144660 -
"Treatment Use of ECMO In Pregnancy or Peripartum Patient."
|
||
| Completed |
NCT04548739 -
Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
|
||
| Recruiting |
NCT04141410 -
Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
|
||
| Not yet recruiting |
NCT05879276 -
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
|
Phase 3 | |
| Enrolling by invitation |
NCT05570864 -
Score TO Predict SHOCK - STOP SHOCK
|
||
| Completed |
NCT02591771 -
Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock
|
Phase 2 | |
| Terminated |
NCT02279979 -
Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial
|
N/A | |
| Completed |
NCT01374867 -
CardShock Study and Registry
|
N/A |